Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS)
Robyn H Guymer, Peter N Dimitrov, Mary Varsamidis, Lyndell L Lim, Paul N Baird, Algis J Vingrys, Luba Robman
CLINICAL INTERVENTIONS IN AGING | DOVE MEDICAL PRESS LTD | Published : 2008
Age-related macular degeneration (AMD) is responsible for the majority of visual impairment in the Western world. The role of cholesterol-lowering medications, HMG Co-A reductase inhibitors or statins, in reducing the risk of AMD or of delaying its progression has not been fully investigated. A 3-year prospective randomized controlled trial of 40 mg simvastatin per day compared to placebo in subjects at high risk of AMD progression is described. This paper outlines the primary aims of the Age-Related Maculopathy Statin Study (ARMSS), and the methodology involved. Standardized clinical grading of macular photographs and comparison of serial macular digital photographs, using the International..View full abstract
Related Projects (1)
Awarded by NHMRC
The ARMSS project is a recipient of funds from The Ian Potter Foundation, John Reid Charitable Trust, and Royal Victorian Eye and Ear Hospital and NHMRC grant 350224 (RHG/AJV). RHG is supported by an NHMRC career development fellowship. Merck, Sharp and Dohme (Sydney, Australia) supplied the active simvastatin and placebo medication for the trial.